In vitro synergy of oxacillin and gentamicin against coagulase-negative staphylococci from blood cultures of neonates with late-onset sepsis

APMIS

Volumn 121, Issue 9, 2013, Pages 859-864

  Brilene, Tatjana ^a   Soeorg, Hiie ^a   Kiis, Merilin ^a   Sepp, Epp ^a   Kõljalg, Siiri ^a,b   Lõivukene, Krista ^b   Jürna Ellam, Marika ^c   Kalinina, Jelena ^a   Štšepetova, Jelena ^a   Metsvaht, Tuuli ^b   Lutsar, Irja ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b TARTU UNIVERSITY HOSPITAL   (Estonia)

^c North Estonia Medical Centre   (Estonia)

Author keywords

Coagulase negative staphylococci; Gentamicin; In vitro synergy; Oxacillin

Indexed keywords

GENTAMICIN; OXACILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; BLOOD SAMPLING; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; NEWBORN; PRIORITY JOURNAL; SEPSIS; STAPHYLOCOCCUS CAPITIS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS HOMINIS; STAPHYLOCOCCUS LENTUS; STAPHYLOCOCCUS SAPROPHYTICUS; STAPHYLOCOCCUS XYLOSUS;

COAGULASE-NEGATIVE STAPHYLOCOCCI; GENTAMICIN; IN VITRO SYNERGY; OXACILLIN;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COAGULASE; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENTAMICINS; HUMANS; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; OXACILLIN; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; VANCOMYCIN;

EID: 84881549597     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12048     Document Type: Article

References (28)

1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110(2 Pt 1):285-91.
2. Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011;96:F9-14.
3. Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics 2000;106:1387-90.
4. van den Hoogen A, Gerards LJ, Verboon-Maciolek MA, Fleer A, Krediet TG. Long-term trends in the epidemiology of neonatal sepsis and antibiotic susceptibility of causative agents. Neonatology 2010;97:22-8.
5. Blayney MP, Al Madani M. Coagulase-negative staphylococcal infections in a neonatal intensive care unit: in vivo response to cloxacillin. Paediatr Child Health 2006;11:659-63.
6. Lawrence SL, Roth V, Slinger R, Toye B, Gaboury I, Lemyre B. Cloxacillin versus vancomycin for presumed late-onset sepsis in the Neonatal Intensive Care Unit and the impact upon outcome of coagulase negative staphylococcal bacteremia: a retrospective cohort study. BMC Pediatr 2005;5:49.
7. Rubin LG, Sánchez PJ, Siegel J, Levine G, Saiman L, Jarvis WR, et al. Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices. Pediatrics 2002;110:e42.
8. Arnold C, Clark R, Bosco J, Shoemaker C, Spitzer AR. Variability in vancomycin use in newborn intensive care units determined from data in an electronic medical record. Infect Control Hosp Epidemiol 2008;29:667-70.
9. Duchon J, Graham Iii P, Della-Latta P, Whittier S, Carp D, Bateman D, et al. Epidemiology of enterococci in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2008;29:374-6.
10. Rasigade JP, Raulin O, Picaud JC, Tellini C, Bes M, Grando J, et al. Methicillin-resistant Staphylococcus capitis with reduced vancomycin susceptibility causes late-onset sepsis in intensive care neonates. PLoS ONE 2012;7:e31548.
11. Isaacs D. Rationing antibiotic use in neonatal units. Arch Dis Child Fetal Neonatal Ed 2000;82:F1-2.
12. Isaacs D, Infections ASGFN. A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal units. Arch Dis Child Fetal Neonatal Ed 2003;88:F89-93.
13. Ferrara A, Dos Santos C, Cimbro M, Gialdroni Grassi G. Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci. Eur J Clin Microbiol Infect Dis 1997;16:535-7.
14. Miranda-Novales G, Leaños-Miranda BE, Vilchis-Pérez M, Solórzano-Santos F. In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains. Ann Clin Microbiol Antimicrob 2006;5:25.
15. CLSI. Performance standards for antimicrobial susceptibility testing. 15th Informational Supplement. Wayne, PA, 2005.
16. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996;40:1914-8.
17. Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat JM, et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:4678-83.
18. Domaracki BE, Evans AM, Venezia RA. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother 2000;44:1394-6.
19. Murakami K, Minamide W, Wada K, Nakamura E, Teraoka H, Watanabe S. Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. J Clin Microbiol 1991;29:2240-4.
20. Tan TY, Lim TP, Lee WH, Sasikala S, Hsu LY, Kwa AL. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother 2011;55:436-8.
21. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003;52:1.
22. Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Söderquist B. In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid. Eur J Clin Microbiol Infect Dis 2010;29:591-5.
23. Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol 2005;43:140-3.
24. Bonapace CR, Bosso JA, Friedrich LV, White RL. Comparison of methods of interpretation of checkerboard synergy testing. Diagn Microbiol Infect Dis 2002;44:363-6.
25. Gülmez D, Cakar A, Sener B, Karakaya J, Hasçelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 2010;16:322-8.
26. Wareham DW, Bean DC. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 2006;5:10.
27. Pankey GA, Ashcraft DS. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay. Diagn Microbiol Infect Dis 2009;63:228-32.
28. Villari P, Sarnataro C, Iacuzio L. Molecular epidemiology of Staphylococcus epidermidis in a neonatal intensive care unit over a three-year period. J Clin Microbiol 2000;38:1740-6.